From Copenhagen, an Update on Fingolimod
From Copenhagen, an Update on Fingolimod
Hello. I am Dr. Aaron Miller, Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York City. I am also Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai. I am here in Copenhagen and attending the 2013 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, a huge gathering of nearly 8000 individuals interested in multiple sclerosis. This has been an interesting meeting, although there haven't been any ground-breaking therapeutic developments.
Over the past few years, we have been treated to an abundance of new agents to treat relapsing forms of multiple sclerosis. We went from no treatments at all in 1992; to the first treatment, introduced in 1993, interferon beta-1b; to 9 or 10 agents that have now been approved in the United States and roughly the same number in Western Europe. This has been a very exciting time. The meeting has taught me that having introduced many new agents, we are now at a stage where we are consolidating that information and beginning to assess how these multiple agents should be used in practice, which patients are best suited for which drug, how should we decide, what risks are involved, and what is the balance between benefits and risks.
Experience With New MS Drugs
Hello. I am Dr. Aaron Miller, Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York City. I am also Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai. I am here in Copenhagen and attending the 2013 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, a huge gathering of nearly 8000 individuals interested in multiple sclerosis. This has been an interesting meeting, although there haven't been any ground-breaking therapeutic developments.
Over the past few years, we have been treated to an abundance of new agents to treat relapsing forms of multiple sclerosis. We went from no treatments at all in 1992; to the first treatment, introduced in 1993, interferon beta-1b; to 9 or 10 agents that have now been approved in the United States and roughly the same number in Western Europe. This has been a very exciting time. The meeting has taught me that having introduced many new agents, we are now at a stage where we are consolidating that information and beginning to assess how these multiple agents should be used in practice, which patients are best suited for which drug, how should we decide, what risks are involved, and what is the balance between benefits and risks.
